This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Scripps Health. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Innovator Spotlight: Darren Sigal and His Contributions to Neuroendocrine Tumor Treatment
Introduction
Darren Sigal is a notable inventor based in San Diego, CA, recognized for his significant contributions to the field of medicine, particularly in the treatment of neuroendocrine tumors (NETs). With one patent to his name, Sigal's innovative methods aim to enhance therapeutic outcomes for individuals affected by this challenging condition.
Latest Patents
Darren Sigal holds a patent titled "Methods of treating a neuroendocrine tumor." This invention discloses methods that involve administering a therapeutically effective amount of an agent that inhibits a tropomyosin receptor kinase (Trk) protein to individuals diagnosed with NETs. His approach specifically targets tumors associated with Trk proteins that have undergone genetic translocations or are linked to NTRK gene fusion proteins. The patent further outlines a systematic method that includes obtaining a genetic material sample from the NET tumor, determining the presence of NTRK translocations or gene fusions, and administering appropriate treatments tailored to the individual's genetic profile.
Career Highlights
Darren Sigal is affiliated with Scripps Health, a renowned healthcare organization that focuses on providing comprehensive medical services and advancing healthcare through innovative practices. His work emphasizes the importance of personalized medicine, reflecting a modern approach in treating complex medical conditions.
Collaborations
Throughout his career, Darren Sigal has likely collaborated with other medical researchers and institutions to bolster the efficacy of his patented methods. While specific details about these collaborations are not provided, the nature of his work suggests a collaborative effort with professionals in oncology and genetic research to continue developing and refining treatment options for NETs.
Conclusion
Darren Sigal's dedicated efforts in researching neuroendocrine tumors position him as a valuable inventor in the medical field. His patent emphasizes the intersection of genetics and therapeutic interventions, paving the way for more effective treatments tailored to individual patients’ needs. As the understanding of NETs evolves, so too will the methods employed to combat them, highlighting the importance of innovation in healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile